この度LINK-Jとして新たな大規模シンポジウム「LINK-J Conference～R＆D × Investment ～」を開催いたします。日本の製薬企業のR＆D部門のパイプラインの紹介及び研究開発戦略を「～今後 10 年の R&D 戦略～」と題して投資を担当する国内外の皆様だけでなく広くライフサイエンスプレイヤーの皆様と共有いたします。
会場ではお食事やお飲み物も用意した立食懇親会と併せてネットワーキングタイムもお楽しみいただけます。日本の製薬企業の最先端技術や最新情報を取得する機会ですので東京日本橋にお越しいただき、海外に向けた日本の製薬産業のエコシステム強化を考える機会としてご活用ください。
皆さまのご参加をお待ちしております。
LINK-J is pleased to announce a new large-scale symposium "LINK-J Conference -R＆D × Investment-". The symposium will introduce the pipelines and R&D strategies of Japanese pharmaceutical companies' R&D divisions and share them with not only domestic and overseas investors but also a wide range of life science players under the title of "R&D Strategy for the Next 10 Years".
A standing reception with food and beverages will be held at the venue, and networking time will also be available. Please come to Tokyo Nihonbashi to learn about the latest information and cutting-edge technologies from Japan's pharmaceutical companies, and use this event as an opportunity to discuss how to strengthen the ecosystem of Japan's pharmaceutical industry for overseas markets.
We look forward to seeing you there.
申込締切
Application Deadline
ONSITE:Until 09:00 on Sunday, May 12, 2024
ONLINE:Until 17:00 on Tuesday, May 14, 2024
※コンビニ / ATM でのお支払いをご希望の場合は、2024年5月13日（月）9:00までにお済ませください。
*If you wish to pay at a convenience store / ATM, please do so by 9:00 a.m. on Monday, May 13, 2024.
※必ず申込締切前にお申込みください。
*Be sure to apply before the application deadline.
領収書について
＊お支払いの確認ができましたら、マイページより領収書/受講票の発行ができます。尚、反映には少し時間がかかる場合がありますのであらかじめご了承ください。*Once payment is confirmed, a receipt and an attendance record can be issued from My Page. Please note that it may take some time for the receipt to be reflected.
プログラム
| Time | Program |
| Opening Remarks | |
| 14:00 | Shunichi Takahashi, Ph.D. (President and Chief Operating Officer, LINK-J) |
| Guest Speeches | |
| 14:05 | Akihisa Shiozaki,MBA (Parliamentary Secretary for Ministry of Health, Labour and Welfare) |
| 14:10 | TBD (Ministry of Health, Labour and Welfare) |
| 14:20 | "METI's Policy for Strengthening the Drug Discovery and Development Ecosystem" Hirokazu Shimoda (Director, Bio-Industry Division, Commerce and Service Industry Policy Group, Ministry of Economy, Trade and Industry) |
| 14:30 | Break for 15 min |
| 6 Pharmaceutical Companies Presentations | |
| 14:45 | Yoshitsugu Shitaka, Ph.D. (Chief Scientific Officer, Astellas Pharma) |
| 15:05 | Drug discovery research and development by leveraging Japan’s strengths Takashi Owa, Ph.D. (Managing Executive Officer, Chief Scientific Officer, Eisai Co., Ltd., Eisai) |
| 15:25 | （Tentative title）"Contemplating the Concept of 'Drug Discovery Capability': Diversity and Strategies in Future Drug Discovery Research " Yasuyoshi Isou, Ph.D. (Senior Executive Officer, Senior Vice President, Drug Research Division, Shionogi) |
| 15:45 | Break for 15 min |
| 16:00 | "CHUGAI Drug Discovery" Hitoshi Iikura, Ph.D. (Director, Head of R&D, Chugai Pharmaceutical) |
| 16:20 | "R&D Strategies of Japanese Pharmaceutical Companies: Present and Future" Masao Nawano, Ph.D./MBA (Vice President, Head of Research Division, Mitsubishi Tanabe Pharma Corporation) |
| 16:40 | Yasushi Kajii, Ph.D. (Head, R&D Japan Region, Takeda Pharmaceutical) |
| Closing Remarks | |
| 17:00 | Akihiko Soyama (Chief Executive Officer, LINK-J) |
| Networking Reception | |
| 17:05‐ | Networking Reception |
登壇者
| プロフィール | |
 |
高橋 俊一 Shunichi Takahashi, Ph.D. LINK-J事務局長 President and Chief Operating Officer, LINK-J |
 |
塩崎 彰久 氏 Akihisa Shiozaki,MBA 厚生労働大臣政務官 Parliamentary Secretary for Ministry of Health, Labour and Welfare 愛媛県松山市出身。１９９９年東京大学法学部卒業、２０００年スタンフォード大学大学院国際政策学修士課程修了、２０１０年ペンシルバニア大学ウォートン校経営学修士課程修了。２００２年弁護士登録。２００６年内閣官房長官秘書官。２０２１年衆議院議員に初当選。現在１期目。２０２３年９月より厚生労働大臣政務官。弁護士時代に多くのスタートアップ支援やヘルスケア関連のコンプライアンス案件に従事。自民党AIの進化と実装に関するPT事務局長などを歴任。 |
| TBD Ministry of Health, Labour and Welfare |
|
 |
下田 裕和 氏 Hirokazu Shimoda 経済産業省商務・サービスグループ 生物化学産業課長 Director, Bio-Industry Division, Commerce and Service Industry Policy Group, Ministry of Economy, Trade and Industry 1999年に通商産業省に入省後、原子力経済被害対応室参事官補佐、生物化学産業課総括補佐、商務流通保安グループ政策企画委員、商務情報政策局政策企画委員を歴任。その後、2016年から2020年まで日本貿易振興機構サンフランシスコ事務所次長の後、情報システム厚生課長を経て、2022年7月より現職。 Hirokazu Shimoda joined METI (Ministry of Economy, Trade and Industry) Japan in 1999, and he had been posted in IT industrial policy sections to promote IT device and software business and cyber security for several years. When the nuclear power plant accident occurred in Fukushima in 2011, he joined the Cabinet Secretariat to create the standards of compensation for the accident suffers. Since he came back to METI in 2013, he produced industrial policy frameworks to promote innovation in biotechnology, pharmaceutical, regenerative medicine sectors, etc. For four years since 2016, he had been an Executive Director of Japan External Trade Organization (JETRO) in San Francisco as a bridge between Japanese and U.S. companies to promote various business innovations. In addition, he had been a fellow at World Economic Forum, Centre for the Fourth Industrial Revolution in San Francisco from 2017 to 2020. He has been in the current position since July 2022. He graduated from the Tokyo Institute of Technology with a degree in electronic and physical engineering. |
 |
志鷹 義嗣 氏 Yoshitsugu Shitaka, Ph.D. アステラス製薬株式会社 専務担当役員 研究担当 Chief Scientific Officer, Astellas Pharma 1996年3月東京大学大学院薬学系研究科博士課程修了。同年4月山之内製薬（現アステラス製薬）に入社。研究本部に所属し創薬研究に19年間携わった後、製品戦略部を経て、2016年5月、Astellas Institute for Regenerative Medicine 社長を務め、2021年4月に専務担当役員 研究担当へ就任、現在に至る。2023年6月より再生医療イノベーションフォーラム（FIRM）代表理事会長。 Dr. Yoshitsugu Shitaka, Ph.D., has been a Chief Scientific Officer of Astellas Pharma Inc. since April 2021. Dr. Shitaka has been an executive of Astellas Pharma Inc. since June 2018 and was president of the Astellas Pharma Institute (AIRM), which was established after Astellas acquired Ocata Therapeutics in May 2016. Prior to that, Dr. Shitaka served as Head of New Product Science Strategy, Product & Portfolio Strategy at Astellas Pharma Inc. in 2015. He served as Therapeutic Area Head, Frontier Disease Research Unit, Drug Discovery Research from 2012 to 2015. He joined Yamanouchi Pharmaceutical, Co., Ltd. (Yamanouchi became a part of Astellas Pharma Inc. in April 2005) in 1996 where he held scientific and management positions of increasing responsibility in Neuroscience, Drug Discovery Research until 2012. He was Visiting Scientist of Washington University School of Medicine in St. Louis from 2009 to 2010. He received his B.Sc., M.Sc., and Ph.D. in Pharmaceutical Sciences from the University of Tokyo in 1991, 1993, and 1996, respectively. He has been Representative Director, Chairperson of Forum for Innovative Regenerative Medicine (FIRM) since June 2023. |
 |
大和 隆志 氏 Takashi Owa, Ph.D. 常務執行役、チーフサイエンティフィックオフィサー Managing Executive Officer, Chief Scientific Officer, Eisai Co., Ltd., 1991年：東京大学大学院薬学系研究科（薬品合成化学研究室）博士課程修了 同年：エーザイ株式会社入社 1996～1998年：ハーバード大学化学・化学生物学科（ケミカルバイオロジー研究室）客員博士研究員 2011年：同社執行役就任 2022年：同社常務執行役・チーフサイエンティフィックオフィサー就任 1991: Completed Ph.D. course at the University of Tokyo Graduate School of Pharmaceutical Sciences (Pharmaceutical Synthetic Organic Chemistry Laboratory) Same year: Joined Eisai Co., Ltd. 1996-1998: Visiting Postdoctoral Scientist, Department of Chemistry and Chemical Biology (Chemical Biology Laboratory), Harvard University 2011: Appointed as an Executive Officer of the company 2022: Appointed as a Managing Executive Officer and Chief Scientific Officer of the company |
 |
井宗 康悦 氏 Yasuyoshi Isou, Ph.D. 塩野義製薬株式会社 上席執行役員 創薬研究本部長 Senior Executive Officer, Senior Vice President, Drug Research Division, Shionogi 1991年京大大学院（薬）修了後、塩野義製薬入社、化学系創薬研究を担当、2016年CMC研究に移り、2019年執行役員CMC研究本部長に就任、上席執行役員研究本部長を経て現在創薬研究本部長。 これまでの主な研究テーマは、開発化合物創製のための医薬品化学研究、抗菌薬、疼痛・中枢神経系薬等の創薬化学研究。 Education: Kyoto University, Faculty of Pharmaceutical Sciences, 04/1985-03/1989, B.S. Kyoto University, Faculty of Pharmaceutical Sciences, 04/1989-03/1991, M.S. Tokushima University, Faculty of Pharmaceutical Sciences, 04/1999, Ph.D. University of Illinois at Chicago, Department of Medicinal Chemistry and Pharmacognosy, 07/2004-06/2005, Research Associates Career: |
 |
飯倉 仁 氏 Hitoshi Iikura, Ph.D. 中外製薬株式会社 取締役 上席執行役員 Director, Head of R&D, Chugai Pharmaceutical 1993年 京都大学卒業 1998年 東京大学大学院博士課程卒業 2000年 中外製薬株式会社入社 2024年 取締役 上席執行役員（現職） 1993 B.Sc., Kyoto University 1998 Ph.D., University of Tokyo 2000 Joined Chugai Pharmaceutical Co., Ltd. 2024 - present Director, Executive Vice President, Chugai Pharmaceutical Co., Ltd. |
 |
縄野 雅夫 氏 Masao Nawano, Ph.D.,MBA 田辺三菱製薬株式会社 創薬本部・本部長 Vice President, Head of Research Division,Mitsubishi Tanabe Pharma Corporation 東京大学大学院農学系研究科修士・博士修了。神戸大学大学院MBA修了。1994年に田辺製薬入社。研究職に従事した後、研究企画から経営戦略等の職務を担当。2016年にミツビシ タナベ ファーマ ホールディングス アメリカの副社長に就任し米国事業戦略を担当。米国でニューロディスカバリーラボを立ち上げ、海外展開を推進。2022年から現職の創薬本部長に就任、日本製薬工業協会の研究開発委員会副委員長就任。 Completed a Master and Ph.D. from the University of Tokyo's Graduate School of Agricultural Science and an MBA from Kobe University. Joined Tanabe Pharmaceutical Company in 1994, transitioning from research roles to research planning and management strategy. In 2016, became Vice President of Mitsubishi Tanabe Pharma Holdings America, overseeing U.S. business strategy and launching the Neuro Discovery Lab to drive global expansion. Currently serves as Head of Research Division and Vice Chairman of the R&D Committee at the Japan Pharmaceutical Manufacturers Association since 2022. |
 |
梶井 靖 氏 Yasushi Kajii, Ph.D. 武田薬品工業株式会社R&D ジャパンリージョン ヘッド Head, R&D Japan Region, Takeda Pharmaceutical 東大大学院修了、農学博士。武田薬品R&Dジャパンリージョンヘッド、T-CiRAプログラムオフィサー。国立精神・神経センター（当時）にて分子精神薬理学研究に従事した後、田辺三菱製薬、アッヴィ、ノバルティスファーマなど国内外の製薬企業にて研究、メディカルアフェアーズ部門等の職を歴任。2019年4月武田薬品工業に入社、2023年4月より現職。早稲田大学総合研究機構研究院教授併任。 Head, R&D Japan Region, Takeda Pharmaceutical Company Ltd. Program Officer for T-CiRA Program. After engaging in molecular psychopharmacological research at the National Center for Psychiatry and Neurology (at that time), held positions such as research and medical affairs at local and global pharmas such as Mitsubishi Tanabe Pharma Corporation, AbbVie, and Novartis. Joined Takeda in April 2019 and assumed the current position in April 2023. Cross-appointed to Professor, Comprehensive Research Organization, Waseda University. |
 |
曽山 明彦 Akihiko Soyama LINK-J常務理事 Chief Executive Officer, LINK-J |
お申込みにつきまして
※LINK-Jサポーター・LINK-J会員・プレスの方は割引コードをお伝えしますので、LINK-Jまでご連絡ください。
*Please contact LINK-J to receive a discount code if you are a LINK-J supporter, LINK-J member or press.
参加費
On-site Participation Fee:(member)5,000YEN （non-member)20,000YEN
Online Participation Fee:(member)0YEN （non-member)20,000YEN
定員
Onsite 100persons, Online500persons
Pre-registration is required to attend. Please note that registration will be on a first-come, first-served basis.
主催
Host：LINK-J
Supprt：Japan Pharmaceutical Manufacturers Association,Pharmaceutical Industrial Policy Committee,Forum for Innovative Regenerative Medicine（FIRM）,Greater Tokyo Biocommunity （GTB）,Biocommunity Kansai（BiocK）
お問い合わせ先
（株式会社JTBコミュニケーションデザイン内）
LINK-J担当：梅原・友近 E-mail：linkj-sympo@jtbcom.co.jp
